Pfizer defeats race-bias lawsuit over minority fellowship program

A federal judge on Friday tossed a lawsuit by a group of medical professionals alleging a fellowship program established by Pfizer Inc to improve diversity within its higher ranks discriminates against white and Asian-American applicants. Do No Harm, a group opposed to what it calls “radical, divisive, and discriminatory ideologies” in healthcare, alleged the drugmaker’s…
Pfizer defeats race-bias lawsuit over minority fellowship program

A federal judge on Friday tossed a lawsuit by a group of medical professionals alleging a fellowship program established by Pfizer Inc to improve diversity within its higher ranks discriminates against white and Asian-American applicants.

Do No Harm, a group opposed to what it calls “radical, divisive, and discriminatory ideologies” in healthcare, alleged the drugmaker’s Breakthrough Fellowship Program was discriminatory because only Blacks, Latinos and Native Americans could apply.

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

But U.S. District Judge Jennifer Rochon in Manhattan ruled the Virginia-based non-profit failed to show it had legal standing to sue Pfizer and seek an injunction as it would not identify by name any members of its group who could not apply to the program due to their race.

She said instead that it submitted “perfunctory” declarations from two anonymous white and Asian-American students at unnamed Ivy League universities “with little to no details about their career and educational goals, employment history, or interests.”

She said even if the two members were identified, Do No Harm had failed to establish they were qualified to apply to the fellowship program, which aims to increase the pipeline of Black, Latino and Native American leaders at the drugmaker.

Rochon, an appointee of Democratic President Joe Biden, said Do No Harm, regardless, lacked standing to pursue the federal claims it asserted under several federal civil rights and anti-discrimination laws.

Pfizer in a statement welcomed the ruling, saying it was “proud of its commitment to diversity, equity, and inclusion.” A lawyer for Do No Harm did not respond to requests for comment.

Pfizer launched the fellowship in 2021. Fellows receive two years of full-time jobs, fully funded master’s degrees, and employment at New York-based Pfizer after completing the program. It aims to enroll 100 fellows by 2025.

The lawsuit was filed in September, a month before the U.S. Supreme Court heard arguments in a pair of cases against Harvard University and the University of North Carolina that could determine the future of affirmative action in higher education.

The Supreme Court, which has 6-3 conservative majority, appeared receptive to arguments by challengers to the universities’ race-conscious admissions policies.

Do No Harm was launched in April, saying it wants to “stop this infiltration of politics in the healthcare system and particularly into medical education before it impacts quality and access to care.” (Reporting by Nate Raymond in Boston; Editing by Leslie Adler)

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
AstraZeneca says COVID shot approved in EU as booster
Read More

AstraZeneca says COVID shot approved in EU as booster

This advertisement has not loaded yet, but your article continues below. Author of the article: Article content Drugmaker AstraZeneca said nL2N2XB1I0 on Monday its COVID-19 vaccine, Vaxzevria, has been approved in the European Union by the region’s medical regulator as a third-dose booster in adults following a panel recommendation last week. (Reporting by Pushkala Aripaka…
U.S. NTSB cuts back on travel over COVID-19 concerns
Read More

U.S. NTSB cuts back on travel over COVID-19 concerns

Author of the article: WASHINGTON — The chair of the National Transportation Safety Board (NTSB) said Wednesday the agency is halting travel unrelated to investigating crashes through at least the end of January. NTSB Chair Jennifer Homendy told employees in an email seen by Reuters that because of “substantial COVID numbers across the country –…
Europe’s Governments Face a Reckoning as Energy Prices Surge
Read More

Europe’s Governments Face a Reckoning as Energy Prices Surge

Author of the article: Bloomberg News Alex Morales and Rachel Morison (Bloomberg) — Europe is gripped by one of the worst energy crunches in history, forcing politicians to step in as soaring prices threaten to leave millions of households unable to pay their bills.  But with market forces signaling that the crisis will last way beyond…